Oxigene

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye. Oxigene

On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). Acute Myeloid Leukemia (AML)

OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer Anaplastic Thyroid Cancer